Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
CTR20171033Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Johnson & Johnson. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on CTR20171033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171033.